Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)

计划入组 20 人 · 首次发布于 2026 年 5 月 29 日

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

计划入组 852 人 · 首次发布于 2024 年 2 月 1 日

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

计划入组 20 人 · 首次发布于 2026 年 4 月 7 日

Therapeutic vaccine (Clostridium difficile infection)

conjugate vaccine (MAPS, Clostridium difficile infection)

Clostridium difficile vaccine

FIRST MEDICAL INFECTION CONTROL ASSOCIATES, INC.

United States

B. Braun Ltd. Centre of Excellence Infection Control

Theriva Biologics

United States

VE303 Shows Promise in Preventing Recurrent Clostridioides difficile Infection

Genetic Analysis Launches GA-map MHI GutHealth Diagnostic Kit for Recurrent C. difficile Infection

Advancements in Clostridioides difficile Treatment and Prevention Highlighted in 2024